Director – Regulatory CMC
Beam Therapeutics
Director – Regulatory CMC
Beam Therapeutics
Develops base editing–based precision medicines
Company Overview:
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Position Overview:
The Director, Regulatory CMC will be responsible for preparing CMC and Quality related health authority agency correspondence and regulatory applications, as well as govern CMC submissions and regulatory compliance support for the development of global products. This position will lead regulatory activities to support high quality CMC sections of regulatory documentation.
Responsibilities:
Qualifications:
The salary range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, education, scope of job, internal comparisons, and market data.
Beam Pay Range 210000 - 260000 USD
Develops base editing–based precision medicines
Beam Therapeutics uses base editing to develop precision genetic medicines aimed at correcting disease-causing mutations. It focuses on R&D and collaborates with pharmaceutical companies and research institutions to fund and advance therapies, earning revenue through partnerships, licensing, upfront and milestone payments, and royalties. The company targets genetic disorders such as sickle cell disease with the goal of delivering lifelong cures, differentiating itself through its emphasis on durable genetic remedies and a science-driven, values-led culture.
Explore more opportunities at Beam Therapeutics